Dutch biotechnology company Crucell N.V. has been granted a patent by the European Patent Office specifically relating to the use of its proprietary PER.C6 technology for the production of vaccines.
The patent (number: EP 1108787 B1) firmly protects the use of the PER.C6 technology for the production of all non-adenoviral viruses, including influenza viruses, for use in veterinary or human vaccines. Further, the patent quite broadly covers the production of any non-adenoviral virus on E1-immortalized cell lines.